MetaCap

Canton Strategic (CNTN) vs Genelux (GNLX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Canton Strategic (CNTN) has outperformed Genelux (GNLX) over the past year, losing 50.6% versus a loss of 56.3%. Genelux is the larger company by market cap ($103.4 million vs $98.8 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

CNTN-50.61%GNLX-56.25%
+133%+30%-73%
Nov 21, 20251 yearNov 20, 2026
CNTN-99.46%GNLX-63.89%
+511%+191%-129%
Jan 23, 20235 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

CNTN versus GNLX key metrics
MetricCNTNGNLX
Share price$1.21$2.17
Market cap$98.78M$103.36M
1-day change-1.63%-4.82%
YTD return-60.07%-50.23%
1-year return-50.61%-56.25%
P/E ratio (TTM)20.17—
EPS (TTM)$0.06$-0.88
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$8.00K
Revenue growth (YoY)—0.00%
Net income (latest FY)$-35.92M$-32.15M
Operating margin—-415175.00%
Net margin—-401812.50%
52-week high$5.83$5.89
52-week low$1.19$1.77
Distance from 52-week high-79.25%-63.16%
Analyst consensus—strong_buy
Avg. price target upside—+767.74%
Average volume763.63K333.31K
Shares outstanding81.64M47.63M
Employees1225
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Canton Strategic

CNTN stock →

Canton Strategic Holdings, Inc. focuses on advancing institutional blockchain adoption and digitizing financial markets in the United States.

Health Care · Biotechnology: Pharmaceutical Preparations · 12 employees

About Genelux

GNLX stock →

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec (olvimulogene nanivacirepvec), a proprietary modified strain of the vaccinia virus indicated for the treatment of ovarian cancer.

Health Care · Biotechnology: Pharmaceutical Preparations · 25 employees

CNTN vs GNLX FAQ

Which is bigger, Canton Strategic or Genelux?

Genelux (GNLX) is larger, with a market capitalization of $103.36M compared with $98.78M for Canton Strategic (CNTN).

Which stock has performed better over the past year, CNTN or GNLX?

CNTN returned -50.61% over the past 12 months, compared with -56.25% for GNLX (price return, excluding dividends). Past performance does not predict future results.

Are Canton Strategic and Genelux in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons